Currently out of the existing stock ratings of Michael King, 94 are a BUY (97.92%), 2 are a HOLD (2.08%).

Michael King

Work Performance Price Targets & Ratings Chart

Analyst Michael King, carries an average stock price target met ratio of 40.66% that have a potential upside of 30.16% achieved within 175 days. Previously, Michael King worked at HCWAINWRIGHT.

Michael King’s has documented 181 price targets and ratings displayed on 23 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on SONN, Sonnet Biotherapeutics Holdings at 23-Aug-2023.

Wall Street Analyst Michael King

Analyst best performing recommendations are on NTLA (INTELLIA THERAPEUTICS).
The best stock recommendation documented was for BMEA (BIOMEA FUSION) at 3/24/2023. The price target of $22 was fulfilled within 4 days with a profit of $6.57 (42.58%) receiving and performance score of 106.45.

Average potential price target upside

of $160.77 (25.43%) on REGN (REGENERON PHARMACEUTICALS).
of $110.33 (71.65%) on CALA (CALITHERA BIOSCIENCES).
of $53.2 (41.62%) on SYRS (SYROS PHARMACEUTICALS).

ALNY Alnylam Pharmaceuticals LTRN Lantern Pharma AGIO Agios Pharm ANAB AnaptysBio CELG Celgene COGT Cogent Biosciences EXEL Exelixis INFI Infinity Pharmaceuticals KTRA Kintara Therapeutics NTLA Intellia Therapeutics REGN Regeneron Pharmaceuticals AGEN Agenus BMEA Biomea Fusion CMPX Compass Therapeutics VINC Vincerx Pharma XNCR Xencor SONN Sonnet Biotherapeutics Holdings JSPR Jasper Therapeutics CALA Calithera Biosciences HOWL Werewolf Therapeutics SYRS Syros Pharmaceuticals SLRX Salarius Pharmaceuticals IDRA Idera Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Luca Issi (RBC)